Comparing Four CGRP Antibodies for Migraine Prevention: What Phase 2 Trials Revealed

Comparative review of published phase 2 randomized controlled trials for all four CGRP-targeting monoclonal antibodies in episodic and chronic migraine prevention. The authors standardized comparisons across trials by examining change from baseline in migraine days, number needed to treat, and odds ratios for adverse events.

This review captured a pivotal moment in headache medicine — when the first disease-specific preventive migraine treatments were emerging. Previous preventive medications (beta-blockers, antidepressants, antiepileptics) were all repurposed from other conditions and came with significant side effects. CGRP antibodies represented the first treatments designed specifically for migraine based on understanding the underlying peptide biology, fundamentally changing how the condition is managed.

The CGRP antibody class represents one of the most successful applications of peptide biology to clinical medicine. Understanding that the neuropeptide CGRP drives migraine pathophysiology led to four approved antibody therapies and multiple small-molecule CGRP receptor antagonists (gepants). This has validated the concept that targeting specific neuropeptide pathways can treat neurological conditions, inspiring similar approaches for other pain conditions and neurological disorders.

This review was based on phase 2 trial data only — smaller and shorter than the subsequent phase 3 trials. Cross-trial comparisons are inherently limited because the studies had different designs, patient populations, and endpoints. Long-term safety data was not available at the time. The review noted that pregnancy safety, cardiovascular effects, and cost-effectiveness required further evaluation — questions that have since been partially addressed.